Four biotech companies announced Series A rounds: Vita Therapeutics, NuvoAir, Enveda Biosciences, and ImmuneID.
Preliminary data from Annovis Bio’s Phase II study of ANVS401 shows significant cognitive improvements in Alzheimer’s patients after only one month of treatment.
Researchers at Arizona State University are experimenting with a compound that might prevent Alzheimer’s and other neurodegenerative diseases, such as Parkinson’s disease, and potentially Down syndrome.
Researchers at Rutgers University-New Brunswick recently published research about a nanotechnology platform that helps identify what happens to specific stem cells.
Newron must delay a trial of the Swiss-listed drugmaker’s prospective schizophrenia medicine evenamide after the U.S. FDA raised concerns about CNS events that emerged in rats and dogs.
Privately held Swedish pharmaceutical company Lobsor Pharmaceuticals AB is eying the U.S. market for a potential treatment for neurodegenerative diseases such as Parkinson’s disease.
An experimental drug could offer hope for restoring damaged brain cells in Parkinson’s patients, scientists said on Wednesday, although they cautioned that a clinical trial was not able to prove the treatment slowed or halted the neurodegenerative disease.
Voyager Therapeutics struck a deal with AbbVie to develop and commercialize vectorized antibodies directed at pathological species of alpha-synuclein for the potential treatment of Parkinson’s disease and other diseases characterized by the abnormal accumulation of misfolded alpha-synuclein protein.
Wexford, Pa.-based Coeptis Pharmaceuticals is buying New York-based Elto Pharma, which is a joint venture between Amarantus Bioscience Holdings and PsychoGenics.
San Mateo, Calif.-based startup CuraSen Therapeutics surged forward with $54.5 million in Series A funding and a leadership team that includes executives from Afferent Pharmaceuticals, a company acquired by Merck in 2016 for $1.2 billion.
